Differences in cardiac output of patients undergoing trans-catheter aortic valve implantation according to their underlying rhythm

Table 3 Clinical characteristics of included patients according to implanted platform, mean ± SD/n (%)/median (interquartile range)

Variable	Non-atrial fibrillation			Atrial fibrillation
	BEV (n = 59)	SEV (n = 48)	P value	BEV (n = 20)	SEV (n = 11)	P value
Age	82 ± 6	82 ± 7	0.53	83 ± 4	79 ± 8	0.14
Male gender	15 (25)	11 (23)	0.76	2 (10)	2 (18)	0.52
Body surface area	1.8 ± 0.2	1.8 ± 0.2	0.47	1.8 ± 0.2	1.8 ± 0.3	0.52
Diabetes	14 (24)	11 (23)	0.92	8 (40)	4 (36)	0.84
Smoker	5 (9)	5 (10)	0.73	0	0
Hemoglobin	123 ± 16	118 ± 17	0.12	120 ± 17	124 ± 20	0.59
Previous MI	5 (9)	5 (10)	0.73	4 (20)	0 (0)	0.11
Chronic lung disease	15 (25)	12 (25)	0.96	6 (30)	3 (27)	0.87
Previous CVA/TIA	8 (14)	6 (13)	0.87	5 (25)	1 (9)	0.28
Previous cardiac surgery	9 (15)	1 (2)	0.02	6 (30)	1 (9)	0.18
Valve size	23 (23-23)	26 (26-29)	< 0.001	23 (23-26)	26 (26-29)	< 0.001
Peak gradient	75 ± 23	80 ± 30	0.26	84 ± 19	86 ± 26	0.80
Mean gradient	45 ± 15	48 ± 21	0.40	51 ± 13	51 ± 21	0.99
Valve area	0.65 ± 0.17	0.71 ± 0.15	0.09	0.56 ± 0.14	0.63 ± 0.16	0.23
Low flow low gradient	15 (25)	8 (17)	0.27	2 (10)	2 (18)	0.52
Preserved LV function	44 (75)	44 (92)	0.021	14 (70)	7 (64)	0.72
Annulus area	379 ± 36	374 ± 44	0.60	388 ± 37	380 ± 41	0.56

MI: Myocardial infarction; CVA: Cerebrovascular event; TIA: Transient ischemic attack; LV: Left ventricle; BEV: Balloon-expandable valve; SEV: Self-expanding valve.